 Home > Active Ingredient News > Endocrine System > Diabetes Obes Metab: Metformin reduces the risk of hospitalization and death in diabetic patients with COVID-19

Diabetes Obes Metab: Metformin reduces the risk of hospitalization and death in diabetic patients with COVID-19

 Last Update: 2022-02-18
 Source: Internet
 Author: User

Tags

what medication metformin used

carrot diabetes

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Since the beginning of 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing a pandemic that killed more than 4 million people in a year

COVID-19 diabetes

In a study published in Diabetes Obesity & Metabolism, a leading journal in the field of metabolic endocrine diseases, researchers compared the association between metformin use and COVID-19 outcomes in a cohort of 31,966 diabetic patients in Lombardy

metformin

The researchers used the COVID-19 Linkable Administrative Region Database to select people with diabetes over the age of 40

In the multivariate model, metformin use was associated with overall mortality (OR, 0.

CONCLUSIONS: In this large cohort, metformin was associated with protective effects on clinical outcomes in patients with COVID-19, suggesting that it may be a potential agent for preventing severe COVID-19 disease , although randomized clinical trials (RCTs) are needed to confirm this.

In this large cohort, metformin was associated with protective effects on clinical outcomes in patients with COVID-19, suggesting that it may be a potential source of pharmacological prophylaxis to prevent severe COVID-19 disease : Metformin use is associated with a decrease in risk of hospitalization and mortality in COVID-19 diabetic patients: a population-based study in Lombardy

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Poly(Vinyl Alcohol) CAS NO.9002-89-5 99% High Quality Factory Supply

CAS No.: 9002-89-5

Industrial Grade

$1-1.2/KG FOB

Factory Wholesale Retail Tirzepatide peptide CAS 2023788-19-2 FEI DUNS Tirezapitde

CAS No.: 2023788-19-2

Pharmacy Grade

$60.00/UNIT EXW

Empagliflozin

CAS No.: 864070-44-0

Pharmacy Grade

$1134/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.